Lyell Immunopharma To Participate in November Investor Events
Key Highlights
- ➤Lyell management to participate in three November investor conferences and meetings
- ➤Goldman Sachs event will frame Lyell’s next-generation lymphoma CAR-T data in 4Q
- ➤Lyell’s LyFE Manufacturing Center is expected to produce more than 1,200 doses annually
Expert Statements
Alexander P. Boardman, MD, Associate Physician, Division of Hematology/Oncology, Mass General Brigham Cancer Institute; Faculty of Medicine, Harvard Medical School
“Framing Lyell’s next-generation lymphoma CAR-T data in 4Q”
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor events:
Goldman Sachs’ RxChange Series: Framing Lyell’s next-generation lymphoma CAR-T data in 4Q Format: Fireside Chat Featured Speaker: Alexander P. Boardman, MD, Associate Physician, Division of Hematology/Oncology, Mass General Brigham Cancer Institute; Faculty of Medicine, Harvard Medical School Date & Time: Thursday, November 5, 2026 at 11:00 am ET Webcast Link: Here
Get started
Create a free account to read the full story.